VY-AADC01 gene therapy in Parkinson's disease: Interim results of the on-going Phase 1b PD-1101 trial

被引：0
|
作者：
Larson, P.
Bankiewicz, K.
Van Laar, A.
Richardson, R.
Ravina, B.
Kells, A.
Boot, B.
Martin, A.
Thompson, M.
Christine, C.
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
315
引用
收藏
页码：S137 / S138
页数：2
相关论文
共 43 条
  • [1] Safety and Efficacy of VY-AADC01 for Medication Refractory Parkinson's Disease in an On-going Phase 1b study
    Christine, C. W.
    Larson, P. S.
    Van Laar, A.
    Richardson, R. M.
    Ravina, B.
    Kells, A.
    Martin, A. J.
    Thompson, M. E.
    Bankiewicz, K. S.
    MOVEMENT DISORDERS, 2019, 34 : S11 - S11
  • [2] Longitudinal analysis of the modified Hoehn and Yahr disease stage in PD-1101, a Phase 1b clinical study of VY-AADC01
    Van Laar, A.
    Richardson, R.
    Sedkov, A.
    Fine, E.
    Bankiewicz, K.
    Ravina, B.
    Larson, P.
    Christine, C.
    MOVEMENT DISORDERS, 2019, 34 : S231 - S232
  • [3] AADC Gene Therapy for Advanced Parkinson's Disease: Interim Results of a Phase 1b Trial
    Ravina, Bernard
    Christine, Chadwick W.
    Larson, Paul S.
    Van Laar, Amber
    Richardson, R. Mark
    Kells, Adrian
    Boot, Brendon
    Martin, Alastair
    Thompson, Marin
    Bankiewicz, Krystof S.
    MOLECULAR THERAPY, 2018, 26 (05) : 32 - 32
  • [4] AADC Gene Therapy (VY-AADC01) Enhances Responses to IV-Levodopa in Parkinson's Disease (PD)
    Nutt, John
    Curtze, Carolin
    Christine, Chadwick W.
    Larson, Paul S.
    Van Laar, Amber
    Richardson, R. Mark
    Boot, Brendon
    Thompson, Marin E.
    Sedkov, Alexander
    Leinonen, Mika
    de Somer, Marc
    Bankiewicz, Krystof S.
    Ravina, Bernard
    ANNALS OF NEUROLOGY, 2018, 84 : S230 - S231
  • [5] Intraputaminal AADC gene therapy for advanced Parkinson's disease: Interim Results of a Phase 1b Trial
    Christine, Chadwick
    Bankiewicz, Krzysztoffs
    Van Laar, Amber
    Richardson, Mark
    Ravina, Bernard
    Kells, Adreian
    Boot, Brendon
    Martin, Alastair
    Thompson, Marin
    Larson, Paul
    NEUROLOGY, 2017, 89 (08) : E99 - E99
  • [6] Intraputaminal AADC gene therapy for advanced Parkinson's disease: interim results of a phase 1b Trial
    Ravina, B.
    Christine, C.
    Bankiewicz, K.
    Van Laar, A.
    Richardson, M.
    Kells, A.
    Boot, B.
    Martin, A.
    Thompson, M.
    Larson, P.
    HUMAN GENE THERAPY, 2017, 28 (12) : A6 - A6
  • [7] Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson's disease
    Christine, C.
    Richardson, R.
    Van Laar, A.
    Thompson, M.
    Herbert, K.
    Li, C.
    Liang, G.
    Fine, E.
    Larson, P.
    MOVEMENT DISORDERS, 2020, 35 : S391 - S392
  • [8] VY-AADC01 in Medically Refractory Parkinson's Disease: Safety and Efficacy of a Phase 1b Dose-Ranging Study 12 Months and Beyond
    Christine, Chadwick W.
    Larson, Paul S.
    Van Laar, Amber
    Richardson, Robert M.
    Ravina, Bernard
    Kells, Adrian
    Boot, Brendon
    Martin, Alastair
    Thompson, Marin
    Bankiewicz, Krystof
    ANNALS OF NEUROLOGY, 2018, 84 : S228 - S228
  • [9] Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease Three-Year Outcomes From the PD-1101 Trial
    Christine, Chadwick W.
    Richardson, R. Mark
    Van Laar, Amber D.
    Thompson, Marin E.
    Fine, Elisabeth M.
    Khwaja, Omar S.
    Li, Chunming
    Liang, Grace S.
    Meier, Andreas
    Roberts, Eiry W.
    Pfau, Madeline L.
    Rodman, Josh R.
    Bankiewicz, Krystof S.
    Larson, Paul S.
    NEUROLOGY, 2022, 98 (01) : E40 - E50
  • [10] PD-1102: A Phase 1 study of VY-AADC01 Administered Using a Posterior Approach in Patients with Parkinson's, Disease and Motor Fluctuations
    Van Laar, Amber
    Richardson, Mark
    Christine, Chadwick
    Factor, Stewart
    Gross, Robert
    Kostyk, Sandra
    Lonser, Russell
    de Somer, Marc
    Sedkov, Alex
    Ravina, Bernard
    Kells, Adrian
    Bankiewicz, Krystof
    Larson, Paul
    NEUROLOGY, 2019, 92 (15)
12345